Rheumatology

Susan Shenoi, MBBS, MS, discusses the recent developments in pediatric rheumatology as well as new therapies and guidelines for treating juvenile idiopathic arthritis.

Vibeke Strand, MD, shares that based on her data, secukinumab is an effective option for treating patients with psoriatic arthritis.

Roy Fleishmann, MD, discusses his Rheumatology Winter Clinical Symposium presentation, “Beyond the package insert: JAK inhibitors (jakinibs): safety issues.”

The American College of Rheumatology has recently updated its recommendations on COVID-19 booster vaccines. Test your knowledge of the latest advice on COVID-19 boosters and how they should be administered with this quiz.

The Chair of the ACR COVID-19 Vaccine Clinical Guidance Task Force shares what was learned from the Omicron variant and how the recommendations for rheumatologists has been affected by it.

Study provides supportive data to confirm the pathogenic role of NEU1 in proliferative lupus nephritis.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending February 18, 2021.

Up to 30% of patients with psoriasis eventually develop inflammatory synovio-entheseal (SE) inflammation.

Arthur Kavanaugh, MD, provides a year in review, including new developments, in rheumatoid arthritis as well as his thoughts on the use of biosimilars.

Roy Fleishmann, MD, discusses his Rheumatology Winter Clinical Symposium presentation, “SLE Update: Novel treatments, and how we assess them.”

Dr. Curtis speaks to how the new ACR COVID-19 vaccine guidelines further protect patients with rheumatic disease.

Arthur Kavanaugh, MD, explains the recent developments in psoriatic arthritis and spondyloarthritis, as well as what rheumatologists should look forward to in 2022.

Chair of the ACR COVID-19 Vaccine Clinical Guidance Task Force, Jeffrey Curtis, discusses the newest vaccine recommendations amid the Omicron variant.

Arthur Kavanaugh, MD, discusses the Rheumatology Winter Clinical Symposium, which runs from February 16 – 19.

Vibeke Strand explains that secukinumab improves psoriatic arthritis in patients regardless of their treatment history.

Fatigue is commonly experienced by patients with rheumatoid arthritis, so how should patients experiencing it be managed? Take this quiz on managing fatigue in rheumatoid arthritis to test your knowledge.

Phase 3 of the FUTURE 5 trial further examined the efficacious effect that secukinumab had on patients with psoriatic arthritis.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending February 11, 2021.

In this Q&A, corresponding author Richard A Furie, MD, discussed the findings of his study comparing obinutuzumab with placebo for the treatment of proliferative lupus nephritis in combination with standard therapies.

According to the study, weight loss may be an effective strategy to prevent or treat pain in patients with hand osteoarthritis.

“Food insecurity may increase an individual’s dependence on inexpensive energy-dense foods that lead to the development of chronic diseases that may affect mental health," investigators stated.

Upadacitinib monotherapy was effective in inhibiting structural joint damage progression in patients with rheumatoid arthritis who were MTX-naïve or had an inadequate response to MTX.

Some patients with rheumatoid arthritis will complain of fatigue, but do you know which patients are most at risk? Take this quiz on the risk factors for fatigue to find out.

Rheumatology Network interviewed Terence Rooney, MD, to discuss the findings of a Network Meta-Analysis that examined the efficacy of guselkumab (TREMFYA) for skin clearance and joint improvements in patients with psoriatic arthritis.

Given the recent concerns regarding venous thromboembolic events in patients with rheumatic disease and pre-existing cardiovascular risk factors being treated with tofacitinib, investigators addressed the occurrence of VTE in patients with PsA.

The American College of Rheumatology (ACR) has published guidance regarding COVID-19 vaccination for patients with rheumatic diseases, with emphasis placed on supplemental and booster doses for patients with rheumatic disease.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending February 4, 2021.

Xavier Mariette, MD, PhD, explains the results of his study examining how rituximab impacts B-cell and T-cell response to COVID-19 vaccine in patients with rheumatic disease.

Mary Wheatley, IOM, CAE, discusses the National Scleroderma Foundation, its recent name change, and the importance of raising awareness of this rare rheumatic condition.

The fifth update from the American College of Rheumatology supports fourth doses of the vaccine for high-risk rheumatic disease patients.